<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="iso-abbrev">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="hwp">cshmcs</journal-id>
<journal-id journal-id-type="pmc">cshmcs</journal-id>
<journal-id journal-id-type="publisher-id">cshmcs</journal-id>
<journal-title-group>
<journal-title>Cold Spring Harbor Molecular Case Studies</journal-title>
</journal-title-group>
<issn pub-type="epub">2373-2873</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28696212</article-id>
<article-id pub-id-type="pmc">5701311</article-id>
<article-id pub-id-type="doi">10.1101/mcs.a001909</article-id>
<article-id pub-id-type="medline">WhitfordMCS001909</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Compound heterozygous <italic>SLC19A3</italic> mutations further refine the critical promoter region for biotin-thiamine-responsive basal ganglia disease</article-title>
<alt-title alt-title-type="left-running">Compound heterozygous <italic>SLC19A3</italic> mutations</alt-title>
<alt-title alt-title-type="right-running">Compound heterozygous <italic>SLC19A3</italic> mutations</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-7833-1502</contrib-id>
<name>
<surname>Whitford</surname>
<given-names>Whitney</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hawkins</surname>
<given-names>Isobel</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glamuzina</surname>
<given-names>Emma</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilson</surname>
<given-names>Francessa</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marshall</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="af4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ashton</surname>
<given-names>Fern</given-names>
</name>
<xref ref-type="aff" rid="af5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Love</surname>
<given-names>Donald R.</given-names>
</name>
<xref ref-type="aff" rid="af5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taylor</surname>
<given-names>Juliet</given-names>
</name>
<xref ref-type="aff" rid="af6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hill</surname>
<given-names>Rosamund</given-names>
</name>
<xref ref-type="aff" rid="af7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lehnert</surname>
<given-names>Klaus</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Snell</surname>
<given-names>Russell G.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jacobsen</surname>
<given-names>Jessie C.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af8">8</xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label>School of Biological Sciences, The University of Auckland, Auckland 1010, New Zealand;</aff>
<aff id="af2"><label>2</label>Adult and Paediatric National Metabolic Service, Starship Children's Hospital, Auckland 1023, New Zealand;</aff>
<aff id="af3"><label>3</label>Department of Paediatric Radiology, Starship Children's Hospital, Auckland 1023, New Zealand;</aff>
<aff id="af4"><label>4</label>Department of Paediatrics and Child Health, Wellington Hospital, Wellington 6021, New Zealand;</aff>
<aff id="af5"><label>5</label>Diagnostic Genetics LabPLUS, Auckland City Hospital, Auckland 1023, New Zealand;</aff>
<aff id="af6"><label>6</label>Genetic Health Service New Zealand, Auckland City Hospital, Auckland 1023, New Zealand;</aff>
<aff id="af7"><label>7</label>Department of Neurology, Auckland City Hospital, Auckland 1023, New Zealand;</aff>
<aff id="af8"><label>8</label>Centre for Brain Research, The University of Auckland, Auckland 1010, New Zealand</aff>
<author-notes>
<corresp>Corresponding author: <email>j.jacobsen@auckland.ac.nz</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2017</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<elocation-id>a001909</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.cshlp.org/site/misc/terms.xhtml">© 2017 Whitford et al.; Published by Cold Spring Harbor Laboratory Press</ext-link>
</copyright-statement>
<copyright-year>2017</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial License</ext-link>, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="WhitfordMCS001909.pdf"></self-uri>
<abstract>
<p>Mutations in the gene <italic>SLC19A3</italic> result in thiamine metabolism dysfunction syndrome 2, also known as biotin-thiamine-responsive basal ganglia disease (BTBGD). This neurometabolic disease typically presents in early childhood with progressive neurodegeneration, including confusion, seizures, and dysphagia, advancing to coma and death. Treatment is possible via supplement of biotin and/or thiamine, with early treatment resulting in significant lifelong improvements. Here we report two siblings who received a refined diagnosis of BTBGD following whole-genome sequencing. Both children inherited compound heterozygous mutations from unaffected parents; a missense single-nucleotide variant (p.G23V) in the first transmembrane domain of the protein, and a 4808-bp deletion in exon 1 encompassing the 5′ UTR and minimal promoter region. This deletion is the smallest promoter deletion reported to date, further defining the minimal promoter region of <italic>SLC19A3</italic>. Unfortunately, one of the siblings died prior to diagnosis, but the other is showing significant improvement after commencement of therapy. This case demonstrates the power of whole-genome sequencing for the identification of structural variants and subsequent diagnosis of rare neurodevelopmental disorders.</p>
</abstract>
<kwd-group>
<kwd>developmental regression</kwd>
<kwd>recurrent encephalopathy</kwd>
<kwd>vitamin B1 deficiency</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>Rutherford Discovery Fellowship from government funding</funding-source>
</award-group>
<award-group id="funding-2">
<funding-source>
<institution-wrap>
<institution>Royal Society of New Zealand </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100001509</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group id="funding-3">
<funding-source>Minds for Minds charitable Trust</funding-source>
</award-group>
<award-group id="funding-4">
<funding-source>
<institution-wrap>
<institution>The University of Auckland </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100001537</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group id="funding-5">
<funding-source>Oakley Mental Health Research Foundation</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="introduction">
<title>INTRODUCTION</title>
<p>Thiamine metabolism dysfunction syndrome 2 (MIM: 607483) is an autosomal recessive neurometabolic condition, resulting from mutations in the solute carrier family 19, member 3 (<italic>SLC19A3</italic>, MIM: 606152) gene, which encodes the human thiamine transporter 2 (hTHTR2) (<xref ref-type="bibr" rid="WHITFORDMCS001909C46">Subramanian et al. 2006a</xref>). The disease was first described in children of consanguineous parents, mainly of Saudi Arabian descent (<xref ref-type="bibr" rid="WHITFORDMCS001909C36">Ozand et al. 1998</xref>). The causative mutation for the disease was subsequently mapped to the <italic>SLC19A3</italic> gene in 2005 (<xref ref-type="bibr" rid="WHITFORDMCS001909C60">Zeng et al. 2005</xref>). The disease typically presents with recurrent bouts of subacute encephalopathy, confusion, seizures, dysarthria, dysphagia, and dystonia, progressing to coma and death in early childhood to adolescence (<xref ref-type="bibr" rid="WHITFORDMCS001909C36">Ozand et al. 1998</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C48">Tabarki et al. 2013</xref>); however, clinical manifestations in infancy have also been reported (<xref ref-type="bibr" rid="WHITFORDMCS001909C45">Sremba et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C59">Ygberg et al. 2016</xref>).</p>
<p>Magnetic resonance imaging (MRI) analysis reveals lesions and necrosis in the caudate nucleus and putamen, with involvement of the infra and supratentorial brain cortex, and the brainstem (<xref ref-type="bibr" rid="WHITFORDMCS001909C36">Ozand et al. 1998</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C48">Tabarki et al. 2013</xref>). Most individuals display normal biochemical and metabolic markers; however, increased levels of lactate and pyruvate in the serum and cerebrospinal fluid (CSF) and increased levels of amino acids in the serum and urine have been observed in a minority of cases (<xref ref-type="bibr" rid="WHITFORDMCS001909C36">Ozand et al. 1998</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C7">Debs et al. 2010</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C3">Alfadhel et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C11">Fassone et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C13">Flønes et al. 2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C14">Gerards et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C37">Pérez-Dueñas et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C48">Tabarki et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C34">Ortigoza-Escobar et al. 2014</xref>, <xref ref-type="bibr" rid="WHITFORDMCS001909C35">2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C43">Schänzer et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C45">Sremba et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C59">Ygberg et al. 2016</xref>).</p>
<p><italic>SLC19A3</italic> belongs to a family of solute carrier genes that includes solute carrier family 19, member 1 (<italic>SLC19A1</italic>) encoding reduced folate transporter (RFC-1), and solute carrier family 19, member 2 (<italic>SLC19A2</italic>) encoding thiamine transporter 1 (hTHTR1) (<xref ref-type="bibr" rid="WHITFORDMCS001909C10">Eudy et al. 2000</xref>). Together, <italic>SLC19A2</italic> and <italic>SLC19A3</italic> are responsible for transportation and homeostasis of thiamine, also known as vitamin B<sub>1</sub>. Thiamine is not endogenously synthesized but is obtained from the diet via absorption through the small intestine. A number of thiamine-dependent enzymes are required for normal cellular function, including oxidative metabolism through the connection of glycolysis with the tricarboxylic acid (TCA) cycle via pyruvate dehydrogenase, the TCA cycle via the α-ketoglutarate complex, and the pentose phosphate shunt (<xref ref-type="bibr" rid="WHITFORDMCS001909C23">Jhala and Hazell 2011</xref>). Although individuals with BTBGD have defective or nonfunctional versions of <italic>SLC19A3</italic>, they do not experience global thiamine deficiency, showing normal levels of thiamine in the blood; however, levels of free-thiamine in the CSF are often significantly reduced (<xref ref-type="bibr" rid="WHITFORDMCS001909C35">Ortigoza-Escobar et al. 2016</xref>).</p>
<p>Expression of SLC19A3 is ubiquitous (<xref ref-type="bibr" rid="WHITFORDMCS001909C53">The GTEx Consortium 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C56">Uhlén et al. 2015</xref>), with expression in the brain restricted to the blood vessels. Specifically, the transporter is localized at the basement membrane and within the perivascular pericytes (<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>). In contrast, SLC19A2 is localized to the luminal side of the endothelial cells of the brain. This stark polarization of the two transporters in the brain differs from their localization in the peripheral tissues (namely, the intestines and kidneys), where SLC19A3 is found at the luminal apical side, whereas SLC19A2 is found both at the luminal and basolateral sides of these organs to maintain levels in the blood (<xref ref-type="bibr" rid="WHITFORDMCS001909C42">Said et al. 2004</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C5">Ashokkumar et al. 2006</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C47">Subramanian et al. 2006b</xref>). The polarization of the two thiamine transporters in the brain but not the kidney or intestine suggests that both transporters are required for transport of thiamine across the blood brain barrier, and it may explain why individuals harboring <italic>SLC19A3</italic> gene mutations develop neurological symptoms and pathology, without having a systemic thiamine deficiency.</p>
<p><xref ref-type="bibr" rid="WHITFORDMCS001909C36">Ozand et al. (1998)</xref> reported that BTBGD patients responded to high doses of biotin with symptoms disappearing within days, with no further episodes of seizures, dystonia, confusion, or coma. Furthermore, clinical signs return to near baseline if treatment is initiated early enough (<xref ref-type="bibr" rid="WHITFORDMCS001909C36">Ozand et al. 1998</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C27">Kono et al. 2009</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C7">Debs et al. 2010</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C3">Alfadhel et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C49">Tabarki et al. 2015</xref>). Early diagnosis is therefore essential, as permanent neurological sequelae including epilepsy, mental retardation, dystonia, and eventually death can occur if left untreated (<xref ref-type="bibr" rid="WHITFORDMCS001909C7">Debs et al. 2010</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C3">Alfadhel et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C48">Tabarki et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C13">Flønes et al. 2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C59">Ygberg et al. 2016</xref>).</p>
<p>Biotin is not a substrate for the thiamine transporter (<xref ref-type="bibr" rid="WHITFORDMCS001909C46">Subramanian et al. 2006a</xref>); thus the method of action for the response to biotin supplementation is unclear. The initial study by Ozand et al. reported no effect of thiamine alone on the clinical presentation of the patients; however, there are conflicting reports as to the effectiveness of biotin or thiamine alone (<xref ref-type="bibr" rid="WHITFORDMCS001909C27">Kono et al. 2009</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C7">Debs et al. 2010</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C58">Yamada et al. 2010</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C3">Alfadhel et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C14">Gerards et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C45">Sremba et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C49">Tabarki et al. 2015</xref>). Most current treatment protocols use a combination of both biotin and thiamine. There is limited physiological understanding as to the rationale behind this treatment approach. It has been suggested that thiamine and biotin act synergistically in the treatment of BTBGD (<xref ref-type="bibr" rid="WHITFORDMCS001909C59">Ygberg et al. 2016</xref>), and there is evidence that biotin is required for the transcription of the <italic>SLC19A3</italic> gene (<xref ref-type="bibr" rid="WHITFORDMCS001909C57">Vlasova et al. 2005</xref>). Thiamine-induced expression of an alternate thiamine transporter (encoded by the <italic>SLC19A2</italic> gene) has been suggested to underlie the clinical benefit seen in BTBGD patients (<xref ref-type="bibr" rid="WHITFORDMCS001909C27">Kono et al. 2009</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C14">Gerards et al. 2013</xref>); however, this has not yet been supported by experimental evidence (<xref ref-type="bibr" rid="WHITFORDMCS001909C32">Nabokina et al. 2013</xref>).</p>
<p>Disease-associated variants, both homozygous and compound heterozygous, have been reported throughout the gene (<xref ref-type="table" rid="WHITFORDMCS001909TB1">Table 1</xref>), and the effect on localization and activity of SLC19A3 has been investigated for a number of mutations. There are mutations that prevent the transport of the SLC19A3 protein to the cell surface, and others that reduce the affinity of the transporter for thiamine by either eliminating or reducing the functional capacity of the transporter (<xref ref-type="bibr" rid="WHITFORDMCS001909C46">Subramanian et al. 2006a</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C27">Kono et al. 2009</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C43">Schänzer et al. 2014</xref>).</p>
<table-wrap id="WHITFORDMCS001909TB1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Previously reported variants in <italic>SLC19A3</italic></p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Chromosomal variant</th>
<th align="center" colspan="1" rowspan="1">Protein variant</th>
<th align="center" colspan="1" rowspan="1">Number of patients</th>
<th align="center" colspan="1" rowspan="1">Domain</th>
<th align="center" colspan="1" rowspan="1">Paper(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5" rowspan="1">Amino acid substitutions</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.68G&gt;T</td>
<td colspan="1" rowspan="1">p.G23V</td>
<td colspan="1" rowspan="1">6</td>
<td colspan="1" rowspan="1">TM1</td>
<td colspan="1" rowspan="1"><xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C35">Ortigoza-Escobar et al. 2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C37">Pérez-Dueñas et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C38">Pronicka et al. 2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C60">Zeng et al. 2005</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.130A&gt;G</td>
<td colspan="1" rowspan="1">p.K44E</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">Ext1</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C27">Kono et al. 2009</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.153A&gt;G</td>
<td colspan="1" rowspan="1">p.I51M</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">Ext1</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C35">Ortigoza-Escobar et al. 2016</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.157A&gt;G</td>
<td colspan="1" rowspan="1">p.N53D</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">Ext1</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C35">Ortigoza-Escobar et al. 2016</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.280T&gt;C</td>
<td colspan="1" rowspan="1">p.W94R</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">TM3</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C43">Schänzer et al. 2014</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.337T&gt;C</td>
<td colspan="1" rowspan="1">p.Y113H</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">TM4</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C13">Flønes et al. 2016</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.416T&gt;A</td>
<td colspan="1" rowspan="1">p.V139G</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">Int3</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C12">Ferreira Whitehead &amp; Leon 2017</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.517A&gt;G</td>
<td colspan="1" rowspan="1">p.N173D</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">TM6</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C11">Fassone et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.527C&gt;A</td>
<td colspan="1" rowspan="1">p.S176Y</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">TM6</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.541T&gt;C</td>
<td colspan="1" rowspan="1">p.S181P</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">TM6</td>
<td colspan="1" rowspan="1"><xref ref-type="bibr" rid="WHITFORDMCS001909C13">Flønes et al. 2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.958G&gt;C</td>
<td colspan="1" rowspan="1">p.E320Q</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">TM8</td>
<td colspan="1" rowspan="1"><xref ref-type="bibr" rid="WHITFORDMCS001909C27">Kono et al. 2009</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C58">Yamada et al. 2010</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.1154T&gt;G</td>
<td colspan="1" rowspan="1">p.L385R</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">TM10</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.1196A&gt;T</td>
<td colspan="1" rowspan="1">p.N399I</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">Int6</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C26">Kohrogi et al. 2015</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.1264 A&gt;G</td>
<td colspan="1" rowspan="1">p.T422A</td>
<td colspan="1" rowspan="1">63</td>
<td colspan="1" rowspan="1">TM11</td>
<td colspan="1" rowspan="1"><xref ref-type="bibr" rid="WHITFORDMCS001909C3">Alfadhel et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C4">Algahtani et al. 2017</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C9">Distelmaier et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C35">Ortigoza-Escobar et al. 2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C49">Tabarki et al. 2015</xref>, <xref ref-type="bibr" rid="WHITFORDMCS001909C48">2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C60">Zeng et al. 2005</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.1332C&gt;G</td>
<td colspan="1" rowspan="1">p.S444R</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">TM12</td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Others</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Chr2: 228,568,440–228,613,489del</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C13">Flønes et al. 2016</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.20C&gt;A</td>
<td colspan="1" rowspan="1">p.S7*</td>
<td colspan="1" rowspan="1">5</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C14">Gerards et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.74dup</td>
<td colspan="1" rowspan="1">p.S26fs</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C45">Sremba et al. 2014</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.81_82dup</td>
<td colspan="1" rowspan="1">p.M28fs</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C45">Sremba et al. 2014</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.507C&gt;G</td>
<td colspan="1" rowspan="1">p.Y169*</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.1173–3992_1314 + 41del4175</td>
<td colspan="1" rowspan="1">p.Q393*fs</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C43">Schänzer et al. 2014</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">r.1173_1314del</td>
<td colspan="1" rowspan="1">p.E393*</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.895_925del</td>
<td colspan="1" rowspan="1">p.V299fs</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.980-14 A&gt;G</td>
<td colspan="1" rowspan="1">p.Y327DfsX8</td>
<td colspan="1" rowspan="1">7</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"><xref ref-type="bibr" rid="WHITFORDMCS001909C7">Debs et al. 2010</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C34">Ortigoza-Escobar et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C35">Ortigoza-Escobar et al. 2016</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C44">Serrano et al. 2012</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.982del</td>
<td colspan="1" rowspan="1">p.A328Lfs*10</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C18">Haack et al. 2014</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.1079dupT</td>
<td colspan="1" rowspan="1">p.L360Ffs*38</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C34">Ortigoza-Escobar et al. 2014</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">c.1403delA</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">
<xref ref-type="bibr" rid="WHITFORDMCS001909C59">Ygberg et al. 2016</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>TM, transmembrane domain; Ext, extracellular domain; Int, intracellular domain.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There is an apparent trigger for episodes of illness that can be identified in up to 50% of children with BTBGD (<xref ref-type="bibr" rid="WHITFORDMCS001909C48">Tabarki et al. 2013</xref>). Bouts of decompensation are often preceded by febrile illness or mild trauma (<xref ref-type="bibr" rid="WHITFORDMCS001909C36">Ozand et al. 1998</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C48">Tabarki et al. 2013</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C34">Ortigoza-Escobar et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C59">Ygberg et al. 2016</xref>). This indicates that there is a background level of thiamine that is transported in the cell with a dysfunctional SLC19A3 transporter that is able to support the energy needs of the brain during normal conditions. There is evidence to suggest the decline and clinical manifestation of the disorder may occur when the energy required exceeds the background levels and there is an inability of the mutant form of the <italic>SLC19A3</italic> gene to undergo the normal stress-induced expression and functional compensation (<xref ref-type="bibr" rid="WHITFORDMCS001909C43">Schänzer et al. 2014</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C35">Ortigoza-Escobar et al. 2016</xref>).</p>
<p>Here we report two siblings who first presented with decompensation, encephalopathy, and seizures following febrile illness. They were subsequently diagnosed with BTBGD following whole-genome sequencing (WGS), which identified compound heterozygous inheritance of a previously reported missense mutation, p.G23V, and a novel 4808-bp promoter deletion. This deletion is the smallest promoter deletion reported for this gene to date, further defining the minimal promoter region for this gene in the context of the disease.</p>
</sec>
<sec id="s2" sec-type="results">
<title>RESULTS</title>
<sec id="s2a">
<title>Clinical Presentation and Family History</title>
<p>The two cases are siblings, New Zealand–born from nonconsanguineous parents of mainly European descent. The proband (AM1005) died at 20 yr of age as a result of respiratory complications of severe dystonic spastic quadriplegia. He was born after a normal pregnancy, had Apgar scores of 5 at 1 min and 9 at 5 min and had 3 d in hospital for treatment of transient tachypnea of the newborn. He progressed normally in his development until he presented at 9 mo of age with seizures in the context of a viral illness. His brain MRI (not shown) revealed bilateral basal ganglia T2 hyperintensity and subdural hematomas. Subsequently he developed epilepsy and three further episodes of definite regression and encephalopathy. Follow-up brain MRI revealed involvement of the basal ganglia, caudate head, lentiform nuclei, and white matter atrophy. From approximately 12 yr of age he was essentially dependent for all activities of daily living but bright and aware of his surroundings. He had extensive neurometabolic workup in 2008 and had mild complex IV deficiency on muscle biopsy. All other investigations were normal and a tentative diagnosis of mitochondrial disease was made.</p>
<p>AM1006 is the proband's full sibling and is currently 7 yr of age. She was born after a normal pregnancy and had normal development until ∼6 mo of age. By 2 yr she had a diagnosis of autism spectrum disorder. She could walk but was ataxic. At nearly 4 yr of age, after a period of steady development, she developed progressive problems with feeding and encephalopathy in the context of a febrile illness. Brain MRI revealed acute restricted diffusion and swelling of the putamen and caudate nuclei (<xref ref-type="fig" rid="WHITFORDMCS001909F1">Fig. 1</xref>B). She was treated with a “mitochondrial cocktail” that included thiamine and improved. This was subsequently withdrawn after 6 mo as its effectiveness was not clear and pyruvate dehydrogenase deficiency was excluded. At 6 yr of age she had a prolonged period of neurological deterioration associated with a markedly abnormal brain MRI (<xref ref-type="fig" rid="WHITFORDMCS001909F1">Fig. 1</xref>C). She lost her ability to swallow and mobilize independently. Given the severity of her presentation she was again trialed on a short course of thiamine and improved. Prior to her diagnosis being made she was gastrostomy-fed, had excessive drooling, was unable to mobilize independently, was hypotonic, and was very irritable. Clinical features of both patients are summarized in <xref ref-type="table" rid="WHITFORDMCS001909TB2">Table 2</xref>.</p>
<fig id="WHITFORDMCS001909F1" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>Magnetic resonance images taken from AM1006. (<italic>A</italic>) Axial T2 brain MRI taken at 3 yr and 5 mo of age prior to the first presentation. (<italic>B</italic>) Axial T2 brain MRI taken during first encephalopathy presentation at 3 yr and 9 mo of age: bilateral symmetrical T2 hyperintensity, swelling, and edema within the caudate nuclei and putamina sparing the globi pallidi and thalami. (<italic>C</italic>) Axial T2 brain MRI taken at 6 yr and 1 mo of age, during the second period of encephalopathy: bilateral symmetrical T2 hyperintensity within caudate nuclei, putamina, thalami, and subcortical white matter of the frontal lobes. There is resolution of basal ganglia swelling relative to the first degenerative episode (<italic>B</italic>).</p>
</caption>
<graphic xlink:href="WhitfordMCS001909_F1"></graphic>
</fig>
<table-wrap id="WHITFORDMCS001909TB2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption>
<p>Clinical summary of BTBGD in patients AM1005 and AM1006</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1">AM1005</th>
<th align="center" colspan="1" rowspan="1">AM1006</th>
<th align="center" colspan="1" rowspan="1">AM1006 post-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4" rowspan="1">Subacute encephalopathy</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Confusion</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Nil further events</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dysarthria</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Nil further events</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dysphagia</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Nil further events</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reduced level of consciousness</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Nil further events</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Chronic symptoms</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dysphagia</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Resolved</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Spasticity</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dystonia</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Quadriparesis</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Inability to walk</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Improving</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Inability to speak</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Improving</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Seizures</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Severe gait ataxia</td>
<td colspan="1" rowspan="1">N/A—immobile</td>
<td colspan="1" rowspan="1">Severe</td>
<td colspan="1" rowspan="1">Moderate</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Nystagmus</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ophthalmoplegia</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">No</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Developmental delay</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Improving</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Biochemical studies of intermediary metabolism normal</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bacterial studies normal</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Viral studies normal</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Preceded by immune response to illness or trauma</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Radiological features</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Swelling and T2 hyperintensity</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Basal ganglia</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Thalami</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Subcortical white matter</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cortex</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cerebral white matter</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cortex</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Midbrain</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Necrosis of</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Head of basal ganglia</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Putamen</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Novel clinical features</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Subdural hematomas present on brain MRI</td>
<td colspan="2" rowspan="1">Autism spectrum disorder diagnosed preencephalopathic event with normal initial MRI scan, choreoathetoid movement disorder</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2b">
<title>Genomic Analyses</title>
<p>Genetic investigation was performed under the hypothesis that the affected siblings carry the same causative variant(s). The siblings were first assessed for copy-number variants using an Affymetrix CytoScan 750K Cytogenetics Array (analyzed using ChAS v.1.2/na32.1 software). Two shared regions of loss of heterozygosity (LOH) were identified; 3.5 Mb at 2p12p11.2 (hg19 Chr2:81,640,336–85,127,909) and 3.2 Mb at 19p13.2 (hg19 Chr19:9,917,692–13,157,540). The first region of LOH encompasses the succinate-CoA ligase, α-subunit (<italic>SUCLG1</italic>) gene that encodes the α-subunit of the enzyme succinate coenzyme A ligase, an enzyme involved in the TCA cycle. Autosomal recessive mutations in this gene result in mitochondrial DNA depletion syndrome 9 (MTDPS9, MIM: 245400) (<xref ref-type="bibr" rid="WHITFORDMCS001909C41">Rouzier et al. 2010</xref>). The symptoms of MTDPS9 were similar to those observed in the two siblings; however, the lack of methylmalonic acid in the urine excluded the 2p12p11.2 LOH as the causative variant.</p>
<p>The second region of LOH contained only one gene: glutaryl CoA dehydrogenase (<italic>GCDH</italic>) which encodes a protein of the same name, involved in the metabolism of lysine, hydroxylysine, and tryptophan. Mutations in this gene result in glutaric acidemia type I (GA1, MIM: 231670) (<xref ref-type="bibr" rid="WHITFORDMCS001909C19">Hedlund et al. 2006</xref>). GA1 was initially considered in the proband to be a strong candidate due to phenotypic similarities; however, urine organic acids, acylcarnitine profile, and enzymology in skin fibroblasts were normal, suggesting that the 19p13.2 was not the causative variant in the patients.</p>
<p>Whole-genome sequencing was performed on genomic DNA from both children, with sequencing statistics detailed in <xref ref-type="table" rid="WHITFORDMCS001909TB3">Table 3</xref>. 166,057 single-nucleotide and indel variants were discovered in the exonic and splice regions of both children. Synonymous variants, variants present in only one sibling, and variants exceeding a frequency of 0.01 in any of the ExAC, HapMap, or 1000 Genomes Project populations were excluded from further consideration. (<xref ref-type="bibr" rid="WHITFORDMCS001909C54">The International Hapmap Consortium 2003</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C52">The 1000 Genomes Project Consortium 2015</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C28">Lek et al. 2016</xref>). Further filtering of the remaining 3481 variants was performed based on protein location, functional impact of the variant, its mode of inheritance (homozygous or compound heterozygous), as well as the biological relevance of the gene. This supervised exclusion of variants revealed compound heterozygous mutations in the <italic>SCL19A3</italic> gene<italic>.</italic> The first is a heterozygous missense mutation, c.68G&gt;T (GRCh37 Chr2:228,566,967; NM_025243.3:c.68G&gt;T) resulting in a glycine-to-valine change (p.G23V) (summarized in <xref ref-type="table" rid="WHITFORDMCS001909TB4">Table 4</xref>). The amino acid is conserved across species to <italic>Drosophila melanogaster</italic> and <italic>Caenorhabditis elegans</italic> (BLASTp, <xref ref-type="bibr" rid="WHITFORDMCS001909C15">Gish and States 1993</xref>). The allele is also extremely rare, present at a frequency of 0.000008239 representing one individual of South Asian descent in the ExAC database (<xref ref-type="bibr" rid="WHITFORDMCS001909C28">Lek et al. 2016</xref>), with no homozygotes present at this position. Confirmation of the single-nucleotide variant in both children and their parents was performed using polymerase chain reaction (PCR) and Sanger sequencing, which verified the mutation was inherited from the mother, who was also heterozygous (<xref ref-type="fig" rid="WHITFORDMCS001909F2">Fig. 2</xref>). The phenotypic presentation in the children corresponded to the description of BTBGD in the literature; however, no other candidate SNP or indels in <italic>SLC19A3</italic> were identified.</p>
<fig id="WHITFORDMCS001909F2" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Family pedigree and corresponding Sanger sequencing electropherograms showing the transmission of the c.68G&gt;T mutation and Chr2: 228,582,252–228,587,059 deletion in the <italic>SLC19A3</italic> gene. The breakpoints for the deletion are indicated by the black arrows, with an insertion of a single base, cytosine, at the breakpoint indicated by the red box. No PCR product was amplifiable from the mother who did not contain the deletion as the PCR was optimized for the 1481-bp deleted product.</p>
</caption>
<graphic xlink:href="WhitfordMCS001909_F2"></graphic>
</fig>
<table-wrap id="WHITFORDMCS001909TB3" orientation="portrait" position="float">
<label>Table 3.</label>
<caption>
<p>Sequencing statistics for whole-genome analysis</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Individual</th>
<th align="center" colspan="1" rowspan="1">Total read pairs</th>
<th align="center" colspan="1" rowspan="1">Total mapped reads</th>
<th align="center" colspan="1" rowspan="1">Average coverage</th>
<th align="center" colspan="1" rowspan="1">Reads at 25 plus coverage</th>
<th align="center" colspan="1" rowspan="1">Coverage at SNP</th>
<th align="center" colspan="1" rowspan="1">Average coverage over deletion</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">AM1005</td>
<td colspan="1" rowspan="1">541,331,895</td>
<td colspan="1" rowspan="1">806,382,669</td>
<td colspan="1" rowspan="1">38.8</td>
<td colspan="1" rowspan="1">99.2%</td>
<td colspan="1" rowspan="1">42</td>
<td colspan="1" rowspan="1">14.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AM1006</td>
<td colspan="1" rowspan="1">569,003,503</td>
<td colspan="1" rowspan="1">765,493,391</td>
<td colspan="1" rowspan="1">36.1</td>
<td colspan="1" rowspan="1">98.8%</td>
<td colspan="1" rowspan="1">32</td>
<td colspan="1" rowspan="1">16.5</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="WHITFORDMCS001909TB4" orientation="portrait" position="float">
<label>Table 4.</label>
<caption>
<p>SLC19A3 variant summary</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Gene</th>
<th align="center" colspan="1" rowspan="1">Chromosome</th>
<th align="center" colspan="1" rowspan="1">HGVS DNA reference</th>
<th align="center" colspan="1" rowspan="1">HGVS protein reference</th>
<th align="center" colspan="1" rowspan="1">Variant type</th>
<th align="center" colspan="1" rowspan="1">Predicted effect</th>
<th align="center" colspan="1" rowspan="1">ClinVar ID</th>
<th align="center" colspan="1" rowspan="1">Parent of origin</th>
<th align="center" colspan="1" rowspan="1">Break points</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">
<italic>SLC19A3</italic>
</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">NM_025243.3</td>
<td colspan="1" rowspan="1">Gly23</td>
<td colspan="1" rowspan="1">Missense</td>
<td colspan="1" rowspan="1">Gly&gt;Val</td>
<td colspan="1" rowspan="1">SCV000574715</td>
<td colspan="1" rowspan="1">Mother</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<italic>SLC19A3</italic>
</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">NC_000002.11</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Deletion</td>
<td colspan="1" rowspan="1">Critical promoter deleted</td>
<td colspan="1" rowspan="1">SCV000574716</td>
<td colspan="1" rowspan="1">Father</td>
<td colspan="1" rowspan="1">228,582,251–228,587,060</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>To investigate the <italic>SLC19A3</italic> locus for structural variants, the WGS read alignments were visualized with Integrated Genomics Viewer (IGV, 2.3.55) (<uri xlink:href="http://software.broadinstitute.org/software/igv">http://software.broadinstitute.org/software/igv</uri>; <xref ref-type="bibr" rid="WHITFORDMCS001909C55">Thorvaldsdóttir et al. 2013</xref>) and inspected for regions of altered coverage and alignment of discordant read pairs. This identified a region of reduced coverage, bordered by discordant reads encompassing exon 1 encoding the 5′ untranslated region (5′ UTR) (<xref ref-type="fig" rid="WHITFORDMCS001909F3">Fig. 3</xref>). The candidate deletion was also detected by copy-number variant detection algorithms: CNVnator (based on alterations in read depth) and BreakDancer (based on paired-end information) (<xref ref-type="bibr" rid="WHITFORDMCS001909C6">Chen et al. 2009</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C2">Abyzov et al. 2011</xref>). The precise breakpoints were mapped by PCR and Sanger sequencing to GRCh37 Chr2:228,582,251–228,587,060 (NC_000002.11:g.228,582,251–228,587,060 del) with the insertion of a cytosine nucleotide (summarized in <xref ref-type="table" rid="WHITFORDMCS001909TB4">Table 4</xref>). This 4808-bp deletion is present in both children and PCR analysis confirmed inheritance from the father. We hypothesize that this deletion abolishes the activity of the promoter, thus eliminating expression from this allele. RNA-seq analysis of RNA from fibroblasts of the surviving child, AM1006, and three unrelated controls did not detect any reads mapping to the <italic>SLC19A3</italic> gene; in contrast <italic>SLC19A1</italic> and <italic>SLC19A2</italic> were well expressed in all samples. Thus, we were unable to categorically determine the effect of the deletion on <italic>SLC19A3</italic> gene expression.</p>
<fig id="WHITFORDMCS001909F3" orientation="portrait" position="float">
<label>Figure 3.</label>
<caption>
<p>Deletion in <italic>SLC19A3</italic>. Integrated Genomics Viewer showing depth of coverage of WGS reads across the 4808-bp deletion (red bar) for both siblings and an unrelated control. The arrows denote the breakpoints for this deletion. The blue bar denotes the 45,049-bp deleted region reported by <xref ref-type="bibr" rid="WHITFORDMCS001909C13">Flønes et al. (2016)</xref>, whereas the green bar denotes the minimal promoter region defined by <xref ref-type="bibr" rid="WHITFORDMCS001909C31">Nabokina and Said (2004)</xref>.</p>
</caption>
<graphic xlink:href="WhitfordMCS001909_F3"></graphic>
</fig>
<p>Thus, the two cases harbor compound heterozygous inherited mutations in the <italic>SLC19A3</italic> gene; a maternally inherited heterozygous p.G23V and a paternally inherited 4808-bp heterozygous deletion in the 5′ region between Chr2:228,582,251 and Chr2:228,587,060, confirming the diagnosis of BTBGD.</p>
</sec>
<sec id="s2c">
<title>Treatment Outcomes</title>
<p>Following the detection of the <italic>SLC19A3</italic> gene mutations, AM1006 was commenced on high-dose (20-mg/kg/day) thiamine and (15-mg/kg/day) biotin at the age of 6 yr and 9 mo. Ten months post commencement of therapy she is now running independently, eating a full diet, and no longer requiring gastrostomy for nutrition. She has had no further encephalopathic events and is communicating with noises and making excellent cognitive progress. She remains intellectually disabled and has autism but is more engaged and interactive and making weekly gains in her development.</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>DISCUSSION</title>
<p>Analysis of WGS data resulted in a molecular diagnosis of BTBGD for two siblings with progressive neurodegeneration. This diagnosis led to successful biotin/thiamine treatment for the surviving child. Both cases harbor compound heterozygous mutations in the <italic>SLC19A3</italic> gene, one inherited from each unaffected parent.</p>
<p>One of the mutations had previously been reported for multiple families with BTBGD, c.68G&gt;T, p.G23V (<xref ref-type="table" rid="WHITFORDMCS001909TB1">Table 1</xref>), whereas the other is a novel 4808-bp deletion encompassing the first exon and predicted promoter region. This deletion is within the much larger 45-kb deletion recently reported by <xref ref-type="bibr" rid="WHITFORDMCS001909C13">Flønes et al. (2016)</xref> and includes the minimal promoter region for the <italic>SLC19A3</italic> gene (<xref ref-type="fig" rid="WHITFORDMCS001909F3">Fig. 3</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C31">Nabokina and Said 2004</xref>). The deletion reported in this study is currently the smallest promoter deletion in this gene identified, further defining the critical promoter region. Taken together, these data suggest that the deletion results in reduced or no expression from this allele. From a molecular diagnostic perspective, the deletion is too small to be detected by aCGH and would have been missed by typical WES approaches (for review, see <xref ref-type="bibr" rid="WHITFORDMCS001909C51">Tan et al. 2014</xref>).</p>
<p>The other mutation (p.G23V) lies within the first transmembrane domain of hTHTR2 (<xref ref-type="fig" rid="WHITFORDMCS001909F4">Fig. 4</xref>), a position that is highly conserved through to invertebrates. The p.G23V mutant SLC19A3 protein has been shown to have minimal effect on targeting of the protein to apical surface of cells, but effectively abolishes the ability of the protein to transport thiamine across the cell membrane (<xref ref-type="bibr" rid="WHITFORDMCS001909C46">Subramanian et al. 2006a</xref>). Based on crystallographic and experimental data of other transporter proteins, the transmembrane domain 1 of <italic>SLC19A3</italic> is one of the four tilted helices that are crucial for the shape and activity of the central hydrophobic pore (<xref ref-type="bibr" rid="WHITFORDMCS001909C50">Tamura et al. 2001</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C20">Hirai et al. 2002</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C1">Abramson et al. 2003</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C21">Huang et al. 2003</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C16">Glaeser et al. 2010</xref>). There is an overrepresentation of glycine in membrane spanning proteins where the helices interact (<xref ref-type="bibr" rid="WHITFORDMCS001909C22">Javadpour et al. 1999</xref>), and substitutions with larger amino acids such as valine in this case may result in steric hindrance in the mutated protein, resulting in conformational changes (<xref ref-type="bibr" rid="WHITFORDMCS001909C46">Subramanian et al. 2006a</xref>). The detrimental effect of glycine-to-valine substitutions has been reported for multiple other solute carrier transporters, resulting in decreased transporter function (<xref ref-type="bibr" rid="WHITFORDMCS001909C61">Zhou et al. 2004</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C30">Li et al. 2012</xref>).</p>
<fig id="WHITFORDMCS001909F4" orientation="portrait" position="float">
<label>Figure 4.</label>
<caption>
<p>Topography of the hTHTR2 protein, consisting of 12 transmembrane domains. Point mutations reported in the literature are indicated as per the legend. The pG23V mutation identified in this study is indicated in red. The topography map is generated from Protter (<xref ref-type="bibr" rid="WHITFORDMCS001909C33">Omasits et al. 2014</xref>).</p>
</caption>
<graphic xlink:href="WhitfordMCS001909_F4"></graphic>
</fig>
<p>Confirming previous reports, the surviving patient responded positively to thiamine and biotin treatment. The exact mechanism through which biotin and thiamine ameliorate the symptoms of BTBGD is unknown. The minimal promoter region for both the <italic>SLC19A2</italic> and <italic>SLC19A3</italic> genes has been previously identified (<xref ref-type="bibr" rid="WHITFORDMCS001909C40">Reidling et al. 2002</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C39">Reidling and Said 2003</xref>; <xref ref-type="bibr" rid="WHITFORDMCS001909C31">Nabokina and Said 2004</xref>). Both promoters contain binding sites for the transcription factor Specificity Protein 1 (SP1), and binding increases the transcription of both genes. Specificity Protein 3 (SP3) binding to the minimal promoter of <italic>SLC19A3</italic> also increases transcription of the gene (<xref ref-type="bibr" rid="WHITFORDMCS001909C31">Nabokina and Said 2004</xref>). Biotin supplementation of cells in culture increases the nuclear abundance of both SP1 and SP3, as well as their association with the respective DNA binding sites, with consequential increases in transcription (<xref ref-type="bibr" rid="WHITFORDMCS001909C17">Griffin et al. 2003</xref>). Therefore, biotin's therapeutic effect may be through an indirect transcriptional activation of the <italic>SLC19A2</italic> and <italic>SLC19A3</italic> genes via SP1 and SP3. This proposed method of action for biotin treatment of BTBGD is in agreement with the hypothesis that the disease is caused by an inability of neurons to undergo a stress-induced increase in <italic>SLC19A3</italic> gene expression (<xref ref-type="bibr" rid="WHITFORDMCS001909C43">Schänzer et al. 2014</xref>). An increase in SP1 expression has been shown to result in the differential up-regulation of <italic>SLC19A3</italic> gene transcription and not <italic>SLC19A2</italic> (<xref ref-type="bibr" rid="WHITFORDMCS001909C32">Nabokina et al. 2013</xref>). Therefore, supplementation of biotin may result in increased transport of thiamine through a semifunctional <italic>SLC19A3</italic> allele (<xref ref-type="bibr" rid="WHITFORDMCS001909C25">Kevelam et al. 2013</xref>).</p>
<p>Critically, the application of WGS was required to detect the small promoter deletion, which lay below the thresholds of detection using conventional high-resolution array-based genome analysis and WES. The identification of the variants reported here resulted in a refined and precise molecular diagnosis and subsequent treatment for the surviving child via supplementation of biotin and thiamine. Early detection and treatment of BTBGD is critical for the long-term survival and outcome for patients. Therefore, these results provide strong support for the expeditious use of WGS in the diagnosis of rare neurodevelopmental disorders.</p>
</sec>
<sec id="s4" sec-type="methods">
<title>METHODS</title>
<sec id="s4a">
<title>DNA Extraction</title>
<p>DNA was extracted from peripheral blood EDTA samples using Gentra Puregene DNA Extraction kit (QIAGEN), according to the manufacturer's instructions.</p>
</sec>
<sec id="s4b">
<title>aCGH Analysis</title>
<p>Genome-wide copy number and SNP analysis was undertaken using an Affymetrix CytoScan 750K Array, according to the manufacturer's instructions. Regions of copy-number change and LOH were determined using the Affymetrix Chromosome Analysis Suite software (ChAS) v.1.2/na32.1 and interpreted with the aid of the UCSC genome browser (<uri xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</uri>; Human Feb. 2009 GRCh37/hg19 assembly).</p>
</sec>
<sec id="s4c">
<title>Whole-Genome Sequencing</title>
<p>WGS services were provided by The Kinghorn Centre for Clinical Genomics (KCCG) at the Garvan Institute using the Illumina HiSeq X Ten instrument. Reads were mapped with Burrows–Wheeler aligner (v 0.7.12) (<xref ref-type="bibr" rid="WHITFORDMCS001909C29">Li and Durbin 2009</xref>) to the 1000 Genomes human genome reference sequence (GRCh37.p13), sequencing statistics in <xref ref-type="table" rid="WHITFORDMCS001909TB3">Table 3</xref>. After removal of optical and PCR duplicates, indels were realigned and base quality scores were recalibrated using the Genome Analysis Toolkit (v. 3.4-0) (<xref ref-type="bibr" rid="WHITFORDMCS001909C8">DePristo et al. 2011</xref>). The alignments for the two children were combined with alignments from 14 unrelated individuals for joint variant discovery with the GATK's HaplotypeCaller and GenotypeGVCFs tools, followed by variant quality score recalibration according to the Broad Institute's Best Practices (<xref ref-type="bibr" rid="WHITFORDMCS001909C8">DePristo et al. 2011</xref>).</p>
<p>Population frequency of SNV and indel variants were obtained from the Exome Aggregation Consortium (ExAC) (<xref ref-type="bibr" rid="WHITFORDMCS001909C28">Lek et al. 2016</xref>), HapMap (<xref ref-type="bibr" rid="WHITFORDMCS001909C54">The International Hapmap Consortium 2003</xref>), and 1000 Genomes Projects (<xref ref-type="bibr" rid="WHITFORDMCS001909C52">The 1000 Genomes Project Consortium 2015</xref>). Bioinformatic identification of CNVs was performed using default parameters of BreakDancer (v 1.4.5) (<xref ref-type="bibr" rid="WHITFORDMCS001909C6">Chen et al. 2009</xref>) and CNVnator (v 0.3) (<xref ref-type="bibr" rid="WHITFORDMCS001909C2">Abyzov et al. 2011</xref>).</p>
<p>WGS alignments and regional variation in read coverage were viewed using the Integrated Genomics Viewer (IGV, 2.3.55) (<uri xlink:href="http://software.broadinstitute.org/software/igv">http://software.broadinstitute.org/software/igv</uri>; <xref ref-type="bibr" rid="WHITFORDMCS001909C55">Thorvaldsdóttir et al. 2013</xref>). Discordant read pairs (pairs mapped further apart than the average library fragment size) were identified with IGV.</p>
</sec>
<sec id="s4d">
<title>Sanger Sequencing</title>
<p>Confirmation of variants was performed using PCR and Sanger sequencing. The forward primer 5′ TTGAGGGAAGCCCTGTATCC 3′, and the reverse primer 5′ GCAGTTCCTGGATTTACCCC 3′ generated a 204-bp product using the Expand High Fidelity PCR System (Roche) with the following thermocycler conditions: 2 min initial denaturation at 94°C, with 30 cycles of 15-sec denaturation at 94°C, 30 sec of annealing at 50°C, and 45 sec of extension at 72°C, followed by 7 min of final extension at 72°C. This 205-bp product includes the C&gt;G missense mutation. The forward primer 5′ TTGCGGCAGCGACATTGATT 3′, and the reverse primer 5′ TGTGCTCGTCTACACATCTTCC 3′ were designed to generate a 6289-bp product in the wild-type allele, and a 1481-bp product in the deleted allele. Thermocycler conditions were optimized so that only the deleted copy was exponentially amplified; 2 min of initial denaturation at 94°C, with 30 cycles of 15-sec denaturation at 94°C, 30 sec annealing at 50°C, and a 3-min extension at 72°C, followed by a 7-min final extension at 68°C. Sanger sequencing was performed by the Genomics Centre, Auckland Science Analytical Services, The University of Auckland, New Zealand. Sanger sequencing data were viewed using Geneious (8.1.5) (<uri xlink:href="http://www.geneious.com">http://www.geneious.com</uri>; <xref ref-type="bibr" rid="WHITFORDMCS001909C24">Kearse et al. 2012</xref>).</p>
</sec>
</sec>
<sec id="s5">
<title>ADDITIONAL INFORMATION</title>
<sec id="s5a">
<title>Data Deposition and Access</title>
<p>Consent was not obtained to deposit full variant calling data publicly; however, mutations have been deposited to ClinVar (<uri xlink:href="https://www.ncbi.nlm.nih.gov/clinvar">https://www.ncbi.nlm.nih.gov/clinvar</uri>) under the accession numbers SCV000574715 and SCV000574716.</p>
</sec>
<sec id="s5b">
<title>Ethics Statement</title>
<p>The genetic analysis and de-identified publication of variants was performed under the approval of the New Zealand Northern B Health and Disability Ethics Committee (12/NTB/59), and parents provided written informed consent.</p>
</sec>
<sec id="s5c">
<title>Acknowledgments</title>
<p>We thank Kristine Boxen, the Genomics Centre, Auckland Science Analytical Services, The University of Auckland, Auckland, New Zealand for assistance with Sanger sequencing. The study was supported by the New Zealand eScience Infrastructure (<uri xlink:href="www.nesi.org.nz">www.nesi.org.nz</uri>).</p>
</sec>
<sec id="s5d">
<title>Author Contributions</title>
<p>W.W. and I.H. performed DNA-based laboratory experiments; W.W., I.H., J.C.J., and K.L. performed data and bioinformatics analysis. E.G. was the metabolic specialist doctor responsible for the care of the patients and contributed to the manuscript. F.W. was the radiologist who collected and reported on the magnetic resonance images. A.M. was the pediatrician responsible for the long-term medical care of the cases. F.A. performed the array-based analysis and identification of shared LOH regions. D.R.L. contributed to sample preparation and clinical confirmation of the variants. J.T. provided genetic counseling for the family following revised molecular diagnosis. R.H., R.G.S., K.L. and J.C.J. conceived the study. W.W. wrote the initial manuscript, and J.C.J. critically reviewed the manuscript. All authors edited and reviewed the final manuscript.</p>
</sec>
<sec id="s5e">
<title>Funding</title>
<p>J.C.J. is supported by a Rutherford Discovery Fellowship from government funding, administered by the Royal Society of New Zealand. The research was funded by the Minds for Minds Charitable Trust, The University of Auckland and the Oakley Mental Health Research Foundation.</p>
</sec>
<sec id="s5f">
<title>Competing Interest Statement</title>
<p>The authors have declared no competing interest.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="WHITFORDMCS001909C1">
<mixed-citation publication-type="journal"><name><surname>Abramson</surname><given-names>J</given-names></name>, <name><surname>Smirnova</surname><given-names>I</given-names></name>, <name><surname>Kasho</surname><given-names>V</given-names></name>, <name><surname>Verner</surname><given-names>G</given-names></name>, <name><surname>Kaback</surname><given-names>HR</given-names></name>, <name><surname>Iwata</surname><given-names>S</given-names></name>. <year>2003</year>
<article-title>Structure and mechanism of the lactose permease of <italic>Escherichia coli</italic></article-title>. <source/>Science
<volume>301</volume>: <fpage>610</fpage>–<lpage>615</lpage>.<pub-id pub-id-type="pmid">12893935</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C2">
<mixed-citation publication-type="journal"><name><surname>Abyzov</surname><given-names>A</given-names></name>, <name><surname>Urban</surname><given-names>AE</given-names></name>, <name><surname>Snyder</surname><given-names>M</given-names></name>, <name><surname>Gerstein</surname><given-names>M</given-names></name>. <year>2011</year>
<article-title>CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing</article-title>. <source/>Genome Res
<volume>21</volume>: <fpage>974</fpage>–<lpage>984</lpage>.<pub-id pub-id-type="pmid">21324876</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C3">
<mixed-citation publication-type="journal"><name><surname>Alfadhel</surname><given-names>M</given-names></name>, <name><surname>Almuntashri</surname><given-names>M</given-names></name>, <name><surname>Jadah</surname><given-names>RH</given-names></name>, <name><surname>Bashiri</surname><given-names>FA</given-names></name>, <name><surname>Al Rifai</surname><given-names>MT</given-names></name>, <name><surname>Al Shalaan</surname><given-names>H</given-names></name>, <name><surname>Al Balwi</surname><given-names>M</given-names></name>, <name><surname>Al Rumayan</surname><given-names>A</given-names></name>, <name><surname>Eyaid</surname><given-names>W</given-names></name>, <name><surname>Al-Twaijri</surname><given-names>W</given-names></name>. <year>2013</year>
<article-title>Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases</article-title>. <source/>Orphanet J Rare Dis
<volume>8</volume>: <fpage>83</fpage>.<pub-id pub-id-type="pmid">23742248</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C4">
<mixed-citation publication-type="journal"><name><surname>Algahtani</surname><given-names>H</given-names></name>, <name><surname>Ghamdi</surname><given-names>S</given-names></name>, <name><surname>Shirah</surname><given-names>B</given-names></name>, <name><surname>Alharbi</surname><given-names>B</given-names></name>, <name><surname>Algahtani</surname><given-names>R</given-names></name>, <name><surname>Bazaid</surname><given-names>A</given-names></name>. <year>2017</year>
<article-title>Biotin–thiamine–responsive basal ganglia disease: catastrophic consequences of delay in diagnosis and treatment</article-title>. <source/>Neurol Res
<volume>39</volume>: <fpage>117</fpage>–<lpage>125</lpage>.<pub-id pub-id-type="pmid">27905264</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C5">
<mixed-citation publication-type="journal"><name><surname>Ashokkumar</surname><given-names>B</given-names></name>, <name><surname>Vaziri</surname><given-names>ND</given-names></name>, <name><surname>Said</surname><given-names>HM</given-names></name>. <year>2006</year>
<article-title>Thiamin uptake by the human-derived renal epithelial (HEK-293) cells: cellular and molecular mechanisms</article-title>. <source/>Am J Physiol Renal Physiol
<volume>291</volume>: <fpage>F796</fpage>–<lpage>F805</lpage>.<pub-id pub-id-type="pmid">16705148</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C6">
<mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Wallis</surname><given-names>JW</given-names></name>, <name><surname>McLellan</surname><given-names>MD</given-names></name>, <name><surname>Larson</surname><given-names>DE</given-names></name>, <name><surname>Kalicki</surname><given-names>JM</given-names></name>, <name><surname>Pohl</surname><given-names>CS</given-names></name>, <name><surname>McGrath</surname><given-names>SD</given-names></name>, <name><surname>Wendl</surname><given-names>MC</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Locke</surname><given-names>DP</given-names></name>, <etal></etal>
<year>2009</year>
<article-title>BreakDancer: an algorithm for high-resolution mapping of genomic structural variation</article-title>. <source/>Nat Methods
<volume>6</volume>: <fpage>677</fpage>–<lpage>681</lpage>.<pub-id pub-id-type="pmid">19668202</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C7">
<mixed-citation publication-type="journal"><name><surname>Debs</surname><given-names>R</given-names></name>, <name><surname>Depienne</surname><given-names>C</given-names></name>, <name><surname>Rastetter</surname><given-names>A</given-names></name>, <name><surname>Bellanger</surname><given-names>A</given-names></name>, <name><surname>Degos</surname><given-names>B</given-names></name>, <name><surname>Galanaud</surname><given-names>D</given-names></name>, <name><surname>Keren</surname><given-names>B</given-names></name>, <name><surname>Lyon-Caen</surname><given-names>O</given-names></name>, <name><surname>Brice</surname><given-names>A</given-names></name>, <name><surname>Sedel</surname><given-names>F</given-names></name>. <year>2010</year>
<article-title>Biotin-responsive basal ganglia disease in ethnic Europeans with novel <italic>SLC19A3</italic> mutations</article-title>. <source/>Arch Neurol
<volume>67</volume>: <fpage>126</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">20065143</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C8">
<mixed-citation publication-type="journal"><name><surname>DePristo</surname><given-names>MA</given-names></name>, <name><surname>Banks</surname><given-names>E</given-names></name>, <name><surname>Poplin</surname><given-names>R</given-names></name>, <name><surname>Garimella</surname><given-names>KV</given-names></name>, <name><surname>Maguire</surname><given-names>JR</given-names></name>, <name><surname>Hartl</surname><given-names>C</given-names></name>, <name><surname>Philippakis</surname><given-names>AA</given-names></name>, <name><surname>del Angel</surname><given-names>G</given-names></name>, <name><surname>Rivas</surname><given-names>MA</given-names></name>, <name><surname>Hanna</surname><given-names>M</given-names></name>, <etal></etal>
<year>2011</year>
<article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title>. <source/>Nat Genet
<volume>43</volume>: <fpage>491</fpage>–<lpage>498</lpage>.<pub-id pub-id-type="pmid">21478889</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C9">
<mixed-citation publication-type="journal"><name><surname>Distelmaier</surname><given-names>F</given-names></name>, <name><surname>Huppke</surname><given-names>P</given-names></name>, <name><surname>Pieperhoff</surname><given-names>P</given-names></name>, <name><surname>Amunts</surname><given-names>K</given-names></name>, <name><surname>Schaper</surname><given-names>J</given-names></name>, <name><surname>Morava</surname><given-names>E</given-names></name>, <name><surname>Mayatepek</surname><given-names>E</given-names></name>, <name><surname>Kohlhase</surname><given-names>J</given-names></name>, <name><surname>Karenfort</surname><given-names>M</given-names></name>. <year>2014</year>
<article-title>Biotin-responsive basal ganglia disease: a treatable differential diagnosis of Leigh syndrome</article-title>. <source/>JIMD Rep
<volume>13</volume>: <fpage>53</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">24166474</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C10">
<mixed-citation publication-type="journal"><name><surname>Eudy</surname><given-names>JD</given-names></name>, <name><surname>Spiegelstein</surname><given-names>O</given-names></name>, <name><surname>Barber</surname><given-names>RC</given-names></name>, <name><surname>Wlodarczyk</surname><given-names>BJ</given-names></name>, <name><surname>Talbot</surname><given-names>J</given-names></name>, <name><surname>Finnell</surname><given-names>RH</given-names></name>. <year>2000</year>
<article-title>Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes</article-title>. <source/>Mol Genet Metab
<volume>71</volume>: <fpage>581</fpage>–<lpage>590</lpage>.<pub-id pub-id-type="pmid">11136550</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C11">
<mixed-citation publication-type="journal"><name><surname>Fassone</surname><given-names>E</given-names></name>, <name><surname>Wedatilake</surname><given-names>Y</given-names></name>, <name><surname>DeVile</surname><given-names>CJ</given-names></name>, <name><surname>Chong</surname><given-names>WK</given-names></name>, <name><surname>Carr</surname><given-names>LJ</given-names></name>, <name><surname>Rahman</surname><given-names>S</given-names></name>. <year>2013</year>
<article-title>Treatable Leigh-like encephalopathy presenting in adolescence</article-title>. <source/>BMJ Case Rep
<volume>2013</volume>: <fpage>200838</fpage>.</mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C12">
<mixed-citation publication-type="journal"><name><surname>Ferreira</surname><given-names>CR</given-names></name>, <name><surname>Whitehead</surname><given-names>MT</given-names></name>, <name><surname>Leon</surname><given-names>E</given-names></name>. <year>2017</year>
<article-title>Biotin-thiamine responsive basal ganglia disease: identification of a pyruvate peak on brain spectroscopy, novel mutation in <italic>SLC19A3</italic>, and calculation of prevalence based on allele frequencies from aggregated next-generation sequencing data</article-title>. <source/>Am J Med Genet A
<volume>173</volume>: <fpage>1502</fpage>–<lpage>1513</lpage>.<pub-id pub-id-type="pmid">28402605</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C13">
<mixed-citation publication-type="journal"><name><surname>Flønes</surname><given-names>I</given-names></name>, <name><surname>Sztromwasser</surname><given-names>P</given-names></name>, <name><surname>Haugarvoll</surname><given-names>K</given-names></name>, <name><surname>Dölle</surname><given-names>C</given-names></name>, <name><surname>Lykouri</surname><given-names>M</given-names></name>, <name><surname>Schwarzlmüller</surname><given-names>T</given-names></name>, <name><surname>Jonassen</surname><given-names>I</given-names></name>, <name><surname>Miletic</surname><given-names>H</given-names></name>, <name><surname>Johansson</surname><given-names>S</given-names></name>, <name><surname>Knappskog</surname><given-names>PM</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Novel SLC19A3 promoter deletion and allelic silencing in biotin-thiamine-responsive basal ganglia encephalopathy</article-title>. <source/>PLoS One
<volume>11</volume>: <fpage>e0149055</fpage>.<pub-id pub-id-type="pmid">26863430</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C14">
<mixed-citation publication-type="journal"><name><surname>Gerards</surname><given-names>M</given-names></name>, <name><surname>Kamps</surname><given-names>R</given-names></name>, <name><surname>Van Oevelen</surname><given-names>J</given-names></name>, <name><surname>Boesten</surname><given-names>I</given-names></name>, <name><surname>Jongen</surname><given-names>E</given-names></name>, <name><surname>De Koning</surname><given-names>B</given-names></name>, <name><surname>Scholte</surname><given-names>HR</given-names></name>, <name><surname>de Angst</surname><given-names>I</given-names></name>, <name><surname>Schoonderwoerd</surname><given-names>K</given-names></name>, <name><surname>Sefiani</surname><given-names>A</given-names></name>, <etal></etal>
<year>2013</year>
<article-title>Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome</article-title>. <source/>Brain
<volume>136</volume>: <fpage>882</fpage>–<lpage>890</lpage>.<pub-id pub-id-type="pmid">23423671</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C15">
<mixed-citation publication-type="journal"><name><surname>Gish</surname><given-names>W</given-names></name>, <name><surname>States</surname><given-names>DJ</given-names></name>. <year>1993</year>
<article-title>Identification of protein coding regions by database similarity search</article-title>. <source/>Nat Genet
<volume>3</volume>: <fpage>266</fpage>–<lpage>272</lpage>.<pub-id pub-id-type="pmid">8485583</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C16">
<mixed-citation publication-type="journal"><name><surname>Glaeser</surname><given-names>H</given-names></name>, <name><surname>Mandery</surname><given-names>K</given-names></name>, <name><surname>Sticht</surname><given-names>H</given-names></name>, <name><surname>Fromm</surname><given-names>MF</given-names></name>, <name><surname>König</surname><given-names>J</given-names></name>. <year>2010</year>
<article-title>Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3</article-title>. <source/>Br J Pharmacol
<volume>159</volume>: <fpage>698</fpage>–<lpage>708</lpage>.<pub-id pub-id-type="pmid">20100277</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C17">
<mixed-citation publication-type="journal"><name><surname>Griffin</surname><given-names>JB</given-names></name>, <name><surname>Rodriguez-Melendez</surname><given-names>R</given-names></name>, <name><surname>Zempleni</surname><given-names>J</given-names></name>. <year>2003</year>
<article-title>The nuclear abundance of transcription factors Sp1 and Sp3 depends on biotin in Jurkat cells</article-title>. <source/>J Nutr
<volume>133</volume>: <fpage>3409</fpage>–<lpage>3415</lpage>.<pub-id pub-id-type="pmid">14608051</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C18">
<mixed-citation publication-type="journal"><name><surname>Haack</surname><given-names>TB</given-names></name>, <name><surname>Klee</surname><given-names>D</given-names></name>, <name><surname>Strom</surname><given-names>TM</given-names></name>, <name><surname>Mayatepek</surname><given-names>E</given-names></name>, <name><surname>Meitinger</surname><given-names>T</given-names></name>, <name><surname>Prokisch</surname><given-names>H</given-names></name>, <name><surname>Distelmaier</surname><given-names>F</given-names></name>. <year>2014</year>
<article-title>Infantile Leigh-like syndrome caused by <italic>SLC19A3</italic> mutations is a treatable disease</article-title>. <source/>Brain
<volume>137</volume>: <fpage>e295</fpage>.<pub-id pub-id-type="pmid">24878502</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C19">
<mixed-citation publication-type="journal"><name><surname>Hedlund</surname><given-names>GL</given-names></name>, <name><surname>Longo</surname><given-names>N</given-names></name>, <name><surname>Pasquali</surname><given-names>M</given-names></name>. <year>2006</year>
<article-title>Glutaric acidemia type 1</article-title>. <source/>Am J Med Genet C: Semin Med Genet
<volume>142C</volume>: <fpage>86</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">16602100</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C20">
<mixed-citation publication-type="journal"><name><surname>Hirai</surname><given-names>T</given-names></name>, <name><surname>Heymann</surname><given-names>JA</given-names></name>, <name><surname>Shi</surname><given-names>D</given-names></name>, <name><surname>Sarker</surname><given-names>R</given-names></name>, <name><surname>Maloney</surname><given-names>PC</given-names></name>, <name><surname>Subramaniam</surname><given-names>S</given-names></name>. <year>2002</year>
<article-title>Three-dimensional structure of a bacterial oxalate transporter</article-title>. <source/>Nat Struct Biol
<volume>9</volume>: <fpage>597</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">12118242</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C21">
<mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Lemieux</surname><given-names>MJ</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>, <name><surname>Auer</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>D-N</given-names></name>. <year>2003</year>
<article-title>Structure and mechanism of the glycerol-3-phosphate transporter from <italic>Escherichia coli</italic></article-title>. <source/>Science
<volume>301</volume>: <fpage>616</fpage>–<lpage>620</lpage>.<pub-id pub-id-type="pmid">12893936</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C22">
<mixed-citation publication-type="journal"><name><surname>Javadpour</surname><given-names>MM</given-names></name>, <name><surname>Eilers</surname><given-names>M</given-names></name>, <name><surname>Groesbeek</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>SO</given-names></name>. <year>1999</year>
<article-title>Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association</article-title>. <source/>Biophys J
<volume>77</volume>: <fpage>1609</fpage>–<lpage>1618</lpage>.<pub-id pub-id-type="pmid">10465772</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C23">
<mixed-citation publication-type="journal"><name><surname>Jhala</surname><given-names>SS</given-names></name>, <name><surname>Hazell</surname><given-names>AS</given-names></name>. <year>2011</year>
<article-title>Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism</article-title>. <source/>Neurochem Int
<volume>58</volume>: <fpage>248</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">21130821</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C24">
<mixed-citation publication-type="journal"><name><surname>Kearse</surname><given-names>M</given-names></name>, <name><surname>Moir</surname><given-names>R</given-names></name>, <name><surname>Wilson</surname><given-names>A</given-names></name>, <name><surname>Stones-Havas</surname><given-names>S</given-names></name>, <name><surname>Cheung</surname><given-names>M</given-names></name>, <name><surname>Sturrock</surname><given-names>S</given-names></name>, <name><surname>Buxton</surname><given-names>S</given-names></name>, <name><surname>Cooper</surname><given-names>A</given-names></name>, <name><surname>Markowitz</surname><given-names>S</given-names></name>, <name><surname>Duran</surname><given-names>C</given-names></name>, <etal></etal>
<year>2012</year>
<article-title>Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data</article-title>. <source/>Bioinformatics
<volume>28</volume>: <fpage>1647</fpage>–<lpage>1649</lpage>.<pub-id pub-id-type="pmid">22543367</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C25">
<mixed-citation publication-type="journal"><name><surname>Kevelam</surname><given-names>SH</given-names></name>, <name><surname>Bugiani</surname><given-names>M</given-names></name>, <name><surname>Salomons</surname><given-names>GS</given-names></name>, <name><surname>Feigenbaum</surname><given-names>A</given-names></name>, <name><surname>Blaser</surname><given-names>S</given-names></name>, <name><surname>Prasad</surname><given-names>C</given-names></name>, <name><surname>Häberle</surname><given-names>J</given-names></name>, <name><surname>Baric</surname><given-names>I</given-names></name>, <name><surname>Bakker</surname><given-names>IM</given-names></name>, <name><surname>Postma</surname><given-names>NL</given-names></name>, <etal></etal>
<year>2013</year>
<article-title>Exome sequencing reveals mutated <italic>SLC19A3</italic> in patients with an early-infantile, lethal encephalopathy</article-title>. <source/>Brain
<volume>136</volume>: <fpage>1534</fpage>–<lpage>1543</lpage>.<pub-id pub-id-type="pmid">23482991</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C26">
<mixed-citation publication-type="journal"><name><surname>Kohrogi</surname><given-names>K</given-names></name>, <name><surname>Imagawa</surname><given-names>E</given-names></name>, <name><surname>Muto</surname><given-names>Y</given-names></name>, <name><surname>Hirai</surname><given-names>K</given-names></name>, <name><surname>Migita</surname><given-names>M</given-names></name>, <name><surname>Mitsubuchi</surname><given-names>H</given-names></name>, <name><surname>Miyake</surname><given-names>N</given-names></name>, <name><surname>Matsumoto</surname><given-names>N</given-names></name>, <name><surname>Nakamura</surname><given-names>K</given-names></name>, <name><surname>Endo</surname><given-names>F</given-names></name>. <year>2015</year>
<article-title>Biotin-responsive basal ganglia disease: a case diagnosed by whole exome sequencing</article-title>. <source/>J Hum Genet
<volume>60</volume>: <fpage>381</fpage>–<lpage>385</lpage>.<pub-id pub-id-type="pmid">25876998</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C27">
<mixed-citation publication-type="journal"><name><surname>Kono</surname><given-names>S</given-names></name>, <name><surname>Miyajima</surname><given-names>H</given-names></name>, <name><surname>Yoshida</surname><given-names>K</given-names></name>, <name><surname>Togawa</surname><given-names>A</given-names></name>, <name><surname>Shirakawa</surname><given-names>K</given-names></name>, <name><surname>Suzuki</surname><given-names>H</given-names></name>. <year>2009</year>
<article-title>Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy</article-title>. <source/>N Engl J Med
<volume>360</volume>: <fpage>1792</fpage>–<lpage>1794</lpage>.<pub-id pub-id-type="pmid">19387023</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C28">
<mixed-citation publication-type="journal"><name><surname>Lek</surname><given-names>M</given-names></name>, <name><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name><surname>Minikel</surname><given-names>EV</given-names></name>, <name><surname>Samocha</surname><given-names>KE</given-names></name>, <name><surname>Banks</surname><given-names>E</given-names></name>, <name><surname>Fennell</surname><given-names>T</given-names></name>, <name><surname>O'Donnell-Luria</surname><given-names>AH</given-names></name>, <name><surname>Ware</surname><given-names>JS</given-names></name>, <name><surname>Hill</surname><given-names>AJ</given-names></name>, <name><surname>Cummings</surname><given-names>BB</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source/>Nature
<volume>536</volume>: <fpage>285</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C29">
<mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Durbin</surname><given-names>R</given-names></name>. <year>2009</year>
<article-title>Fast and accurate short read alignment with Burrows–Wheeler transform</article-title>. <source/>Bioinformatics
<volume>25</volume>: <fpage>1754</fpage>–<lpage>1760</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C30">
<mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>N</given-names></name>, <name><surname>Hong</surname><given-names>W</given-names></name>, <name><surname>Huang</surname><given-names>H</given-names></name>, <name><surname>Lu</surname><given-names>H</given-names></name>, <name><surname>Lin</surname><given-names>G</given-names></name>, <name><surname>Hong</surname><given-names>M</given-names></name>. <year>2012</year>
<article-title>Identification of amino acids essential for estrone-3-sulfate transport within transmembrane domain 2 of organic anion transporting polypeptide 1B1</article-title>. <source/>PLoS One
<volume>7</volume>: <fpage>e36647</fpage>.<pub-id pub-id-type="pmid">22574206</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C31">
<mixed-citation publication-type="journal"><name><surname>Nabokina</surname><given-names>SM</given-names></name>, <name><surname>Said</surname><given-names>HM</given-names></name>. <year>2004</year>
<article-title>Characterization of the 5′-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies</article-title>. <source/>Am J Physiol Gastrointest Liver Physiol
<volume>287</volume>: <fpage>G822</fpage>–<lpage>G829</lpage>.<pub-id pub-id-type="pmid">15217784</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C32">
<mixed-citation publication-type="journal"><name><surname>Nabokina</surname><given-names>SM</given-names></name>, <name><surname>Subramanian</surname><given-names>VS</given-names></name>, <name><surname>Valle</surname><given-names>JE</given-names></name>, <name><surname>Said</surname><given-names>HM</given-names></name>. <year>2013</year>
<article-title>Adaptive regulation of human intestinal thiamine uptake by extracellular substrate level: a role for THTR-2 transcriptional regulation</article-title>. <source/>Am J Physiol Gastrointest Liver Physiol
<volume>305</volume>: <fpage>G593</fpage>–<lpage>G599</lpage>.<pub-id pub-id-type="pmid">23989004</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C33">
<mixed-citation publication-type="journal"><name><surname>Omasits</surname><given-names>U</given-names></name>, <name><surname>Ahrens</surname><given-names>CH</given-names></name>, <name><surname>Müller</surname><given-names>S</given-names></name>, <name><surname>Wollscheid</surname><given-names>B</given-names></name>. <year>2014</year>
<article-title>Protter: interactive protein feature visualization and integration with experimental proteomic data</article-title>. <source/>Bioinformatics
<volume>30</volume>: <fpage>884</fpage>–<lpage>886</lpage>.<pub-id pub-id-type="pmid">24162465</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C34">
<mixed-citation publication-type="journal"><name><surname>Ortigoza-Escobar</surname><given-names>JD</given-names></name>, <name><surname>Serrano</surname><given-names>M</given-names></name>, <name><surname>Molero</surname><given-names>M</given-names></name>, <name><surname>Oyarzabal</surname><given-names>A</given-names></name>, <name><surname>Rebollo</surname><given-names>M</given-names></name>, <name><surname>Muchart</surname><given-names>J</given-names></name>, <name><surname>Artuch</surname><given-names>R</given-names></name>, <name><surname>Rodríguez-Pombo</surname><given-names>P</given-names></name>, <name><surname>Pérez-Dueñas</surname><given-names>B</given-names></name>. <year>2014</year>
<article-title>Thiamine transporter-2 deficiency: outcome and treatment monitoring</article-title>. <source/>Orphanet J Rare Dis
<volume>9</volume>: <fpage>92</fpage>.<pub-id pub-id-type="pmid">24957181</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C35">
<mixed-citation publication-type="journal"><name><surname>Ortigoza-Escobar</surname><given-names>JD</given-names></name>, <name><surname>Molero-Luis</surname><given-names>M</given-names></name>, <name><surname>Arias</surname><given-names>A</given-names></name>, <name><surname>Oyarzabal</surname><given-names>A</given-names></name>, <name><surname>Darín</surname><given-names>N</given-names></name>, <name><surname>Serrano</surname><given-names>M</given-names></name>, <name><surname>Garcia-Cazorla</surname><given-names>A</given-names></name>, <name><surname>Tondo</surname><given-names>M</given-names></name>, <name><surname>Hernández</surname><given-names>M</given-names></name>, <name><surname>Garcia-Villoria</surname><given-names>J</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome</article-title>. <source/>Brain
<volume>139</volume>: <fpage>31</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">26657515</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C36">
<mixed-citation publication-type="journal"><name><surname>Ozand</surname><given-names>PT</given-names></name>, <name><surname>Gascon</surname><given-names>GG</given-names></name>, <name><surname>Al Essa</surname><given-names>M</given-names></name>, <name><surname>Joshi</surname><given-names>S</given-names></name>, <name><surname>Al Jishi</surname><given-names>E</given-names></name>, <name><surname>Bakheet</surname><given-names>S</given-names></name>, <name><surname>Al Watban</surname><given-names>J</given-names></name>, <name><surname>Al-Kawi</surname><given-names>MZ</given-names></name>, <name><surname>Dabbagh</surname><given-names>O</given-names></name>. <year>1998</year>
<article-title>Biotin-responsive basal ganglia disease: a novel entity</article-title>. <source/>Brain
<volume>121</volume>: <fpage>1267</fpage>–<lpage>1279</lpage>.<pub-id pub-id-type="pmid">9679779</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C37">
<mixed-citation publication-type="journal"><name><surname>Pérez-Dueñas</surname><given-names>B</given-names></name>, <name><surname>Serrano</surname><given-names>M</given-names></name>, <name><surname>Rebollo</surname><given-names>M</given-names></name>, <name><surname>Muchart</surname><given-names>J</given-names></name>, <name><surname>Gargallo</surname><given-names>E</given-names></name>, <name><surname>Dupuits</surname><given-names>C</given-names></name>, <name><surname>Artuch</surname><given-names>R</given-names></name>. <year>2013</year>
<article-title>Reversible lactic acidosis in a newborn with thiamine transporter-2 deficiency</article-title>. <source/>Pediatrics
<volume>131</volume>: <fpage>e1670</fpage>–<lpage>e1675</lpage>.<pub-id pub-id-type="pmid">23589815</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C38">
<mixed-citation publication-type="journal"><name><surname>Pronicka</surname><given-names>E</given-names></name>, <name><surname>Piekutowska-Abramczuk</surname><given-names>D</given-names></name>, <name><surname>Ciara</surname><given-names>E</given-names></name>, <name><surname>Trubicka</surname><given-names>J</given-names></name>, <name><surname>Rokicki</surname><given-names>D</given-names></name>, <name><surname>Karkucińska-Więckowska</surname><given-names>A</given-names></name>, <name><surname>Pajdowska</surname><given-names>M</given-names></name>, <name><surname>Jurkiewicz</surname><given-names>E</given-names></name>, <name><surname>Halat</surname><given-names>P</given-names></name>, <name><surname>Kosińska</surname><given-names>J</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>New perspective in diagnostics of mitochondrial disorders: two years’ experience with whole-exome sequencing at a national paediatric centre</article-title>. <source/>J Transl Med
<volume>14</volume>: <fpage>174</fpage>.<pub-id pub-id-type="pmid">27290639</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C39">
<mixed-citation publication-type="journal"><name><surname>Reidling</surname><given-names>JC</given-names></name>, <name><surname>Said</surname><given-names>HM</given-names></name>. <year>2003</year>
<article-title>In vitro and in vivo characterization of the minimal promoter region of the human thiamin transporter SLC19A2</article-title>. <source/>Am J of Physiol Cell Physiol
<volume>285</volume>: <fpage>C633</fpage>–<lpage>C641</lpage>.<pub-id pub-id-type="pmid">12900388</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C40">
<mixed-citation publication-type="journal"><name><surname>Reidling</surname><given-names>JC</given-names></name>, <name><surname>Subramanian</surname><given-names>VS</given-names></name>, <name><surname>Dudeja</surname><given-names>PK</given-names></name>, <name><surname>Said</surname><given-names>HM</given-names></name>. <year>2002</year>
<article-title>Expression and promoter analysis of SLC19A2 in the human intestine</article-title>. <source/>Biochim Biophys Acta
<volume>1561</volume>: <fpage>180</fpage>–<lpage>187</lpage>.<pub-id pub-id-type="pmid">11997118</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C41">
<mixed-citation publication-type="journal"><name><surname>Rouzier</surname><given-names>C</given-names></name>, <name><surname>Le Guédard-Méreuze</surname><given-names>S</given-names></name>, <name><surname>Fragaki</surname><given-names>K</given-names></name>, <name><surname>Serre</surname><given-names>V</given-names></name>, <name><surname>Miro</surname><given-names>J</given-names></name>, <name><surname>Tuffery-Giraud</surname><given-names>S</given-names></name>, <name><surname>Chaussenot</surname><given-names>A</given-names></name>, <name><surname>Bannwarth</surname><given-names>S</given-names></name>, <name><surname>Caruba</surname><given-names>C</given-names></name>, <name><surname>Ostergaard</surname><given-names>E</given-names></name>, <etal></etal>
<year>2010</year>
<article-title>The severity of phenotype linked to <italic>SUCLG1</italic> mutations could be correlated with residual amount of SUCLG1 protein</article-title>. <source/>J Med Genet
<volume>47</volume>: <fpage>670</fpage>–<lpage>676</lpage>.<pub-id pub-id-type="pmid">20693550</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C42">
<mixed-citation publication-type="journal"><name><surname>Said</surname><given-names>HM</given-names></name>, <name><surname>Balamurugan</surname><given-names>K</given-names></name>, <name><surname>Subramanian</surname><given-names>VS</given-names></name>, <name><surname>Marchant</surname><given-names>JS</given-names></name>. <year>2004</year>
<article-title>Expression and functional contribution of hTHTR-2 in thiamin absorption in human intestine</article-title>. <source/>Am J Physiol Gastrointest Liver Physiol
<volume>286</volume>: <fpage>G491</fpage>–<lpage>G498</lpage>.<pub-id pub-id-type="pmid">14615284</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C43">
<mixed-citation publication-type="journal"><name><surname>Schänzer</surname><given-names>A</given-names></name>, <name><surname>Döring</surname><given-names>B</given-names></name>, <name><surname>Ondrouschek</surname><given-names>M</given-names></name>, <name><surname>Goos</surname><given-names>S</given-names></name>, <name><surname>Garvalov</surname><given-names>BK</given-names></name>, <name><surname>Geyer</surname><given-names>J</given-names></name>, <name><surname>Acker</surname><given-names>T</given-names></name>, <name><surname>Neubauer</surname><given-names>B</given-names></name>, <name><surname>Hahn</surname><given-names>A</given-names></name>. <year>2014</year>
<article-title>Stress-induced upregulation of SLC19A3 is impaired in biotin-thiamine-responsive basal ganglia disease</article-title>. <source/>Brain Pathol
<volume>24</volume>: <fpage>270</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">24372704</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C44">
<mixed-citation publication-type="journal"><name><surname>Serrano</surname><given-names>M</given-names></name>, <name><surname>Rebollo</surname><given-names>M</given-names></name>, <name><surname>Depienne</surname><given-names>C</given-names></name>, <name><surname>Rastetter</surname><given-names>A</given-names></name>, <name><surname>Fernández-Álvarez</surname><given-names>E</given-names></name>, <name><surname>Muchart</surname><given-names>J</given-names></name>, <name><surname>Martorell</surname><given-names>L</given-names></name>, <name><surname>Artuch</surname><given-names>R</given-names></name>, <name><surname>Obeso</surname><given-names>JA</given-names></name>, <name><surname>Pérez-Dueñas</surname><given-names>B</given-names></name>. <year>2012</year>
<article-title>Reversible generalized dystonia and encephalopathy from thiamine transporter 2 deficiency</article-title>. <source/>Mov Disord
<volume>27</volume>: <fpage>1295</fpage>–<lpage>1298</lpage>.<pub-id pub-id-type="pmid">22777947</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C45">
<mixed-citation publication-type="journal"><name><surname>Sremba</surname><given-names>LJ</given-names></name>, <name><surname>Chang</surname><given-names>RC</given-names></name>, <name><surname>Elbalalesy</surname><given-names>NM</given-names></name>, <name><surname>Cambray-Forker</surname><given-names>EJ</given-names></name>, <name><surname>Abdenur</surname><given-names>JE</given-names></name>. <year>2014</year>
<article-title>Whole exome sequencing reveals compound heterozygous mutations in <italic>SLC19A3</italic> causing biotin-thiamine responsive basal ganglia disease</article-title>. <source/>Mol Genet Metab Rep
<volume>1</volume>: <fpage>368</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">27896110</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C46">
<mixed-citation publication-type="journal"><name><surname>Subramanian</surname><given-names>VS</given-names></name>, <name><surname>Marchant</surname><given-names>JS</given-names></name>, <name><surname>Said</surname><given-names>HM</given-names></name>. <year>2006a</year>
<article-title>Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2</article-title>. <source/>Am J Physiol Cell Physiol
<volume>291</volume>: <fpage>C851</fpage>–<lpage>C859</lpage>.<pub-id pub-id-type="pmid">16790503</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C47">
<mixed-citation publication-type="journal"><name><surname>Subramanian</surname><given-names>VS</given-names></name>, <name><surname>Marchant</surname><given-names>JS</given-names></name>, <name><surname>Said</surname><given-names>HM</given-names></name>. <year>2006b</year>
<article-title>Targeting and trafficking of the human thiamine transporter-2 in epithelial cells</article-title>. <source/>J Biol Chem
<volume>281</volume>: <fpage>5233</fpage>–<lpage>5245</lpage>.<pub-id pub-id-type="pmid">16371350</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C48">
<mixed-citation publication-type="journal"><name><surname>Tabarki</surname><given-names>B</given-names></name>, <name><surname>Al-Shafi</surname><given-names>S</given-names></name>, <name><surname>Al-Shahwan</surname><given-names>S</given-names></name>, <name><surname>Azmat</surname><given-names>Z</given-names></name>, <name><surname>Al-Hashem</surname><given-names>A</given-names></name>, <name><surname>Al-Adwani</surname><given-names>N</given-names></name>, <name><surname>Biary</surname><given-names>N</given-names></name>, <name><surname>Al-Zawahmah</surname><given-names>M</given-names></name>, <name><surname>Khan</surname><given-names>S</given-names></name>, <name><surname>Zuccoli</surname><given-names>G</given-names></name>. <year>2013</year>
<article-title>Biotin-responsive basal ganglia disease revisited</article-title>. <source/>Neurology
<volume>80</volume>: <fpage>261</fpage>–<lpage>267</lpage>.<pub-id pub-id-type="pmid">23269594</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C49">
<mixed-citation publication-type="journal"><name><surname>Tabarki</surname><given-names>B</given-names></name>, <name><surname>Alfadhel</surname><given-names>M</given-names></name>, <name><surname>Alshahwan</surname><given-names>S</given-names></name>, <name><surname>Hundallah</surname><given-names>K</given-names></name>, <name><surname>Alshafi</surname><given-names>S</given-names></name>, <name><surname>Alhashem</surname><given-names>A</given-names></name>. <year>2015</year>
<article-title>Treatment of biotin-responsive basal ganglia disease: open comparative study between the combination of biotin plus thiamine versus thiamine alone</article-title>. <source/>Eur J Paediatr Neurol
<volume>19</volume>: <fpage>547</fpage>–<lpage>552</lpage>.<pub-id pub-id-type="pmid">26095097</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C50">
<mixed-citation publication-type="journal"><name><surname>Tamura</surname><given-names>N</given-names></name>, <name><surname>Konishi</surname><given-names>S</given-names></name>, <name><surname>Iwaki</surname><given-names>S</given-names></name>, <name><surname>Kimura-Someya</surname><given-names>T</given-names></name>, <name><surname>Nada</surname><given-names>S</given-names></name>, <name><surname>Yamaguchi</surname><given-names>A</given-names></name>. <year>2001</year>
<article-title>Complete cysteine-scanning mutagenesis and site-directed chemical modification of the Tn10-encoded metal-tetracycline/H<sup>+</sup> antiporter</article-title>. <source/>J Biol Chem
<volume>276</volume>: <fpage>20330</fpage>–<lpage>20339</lpage>.<pub-id pub-id-type="pmid">11278375</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C51">
<mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>R</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Kleinstein</surname><given-names>SE</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Guo</surname><given-names>H</given-names></name>, <name><surname>Jiang</surname><given-names>Q</given-names></name>, <name><surname>Allen</surname><given-names>AS</given-names></name>, <name><surname>Zhu</surname><given-names>M</given-names></name>. <year>2014</year>
<article-title>An evaluation of copy number variation detection tools from whole-exome sequencing data</article-title>. <source/>Hum Mutat
<volume>35</volume>: <fpage>899</fpage>–<lpage>907</lpage>.<pub-id pub-id-type="pmid">24599517</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C52">
<mixed-citation publication-type="journal"><collab>The 1000 Genomes Project Consortium</collab>. <year>2015</year>
<article-title>A global reference for human genetic variation</article-title>. <source/>Nature
<volume>526</volume>: <fpage>68</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">26432245</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C53">
<mixed-citation publication-type="journal"><collab>The GTEx Consortium</collab>. <year>2013</year>
<article-title>The Genotype-Tissue Expression (GTEx) Project</article-title>. <source/>Nat Genet
<volume>45</volume>: <fpage>580</fpage>–<lpage>585</lpage>.<pub-id pub-id-type="pmid">23715323</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C54">
<mixed-citation publication-type="journal"><collab>The International Hapmap Consortium</collab>. <year>2003</year>
<article-title>The International HapMap Project</article-title>. <source/>Nature
<volume>426</volume>: <fpage>789</fpage>–<lpage>796</lpage>.<pub-id pub-id-type="pmid">14685227</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C55">
<mixed-citation publication-type="journal"><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name>, <name><surname>Robinson</surname><given-names>JT</given-names></name>, <name><surname>Mesirov</surname><given-names>JP</given-names></name>. <year>2013</year>
<article-title>Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration</article-title>. <source/>Brief Bioinform
<volume>14</volume>: <fpage>178</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">22517427</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C56">
<mixed-citation publication-type="journal"><name><surname>Uhlén</surname><given-names>M</given-names></name>, <name><surname>Fagerberg</surname><given-names>L</given-names></name>, <name><surname>Hallström</surname><given-names>BM</given-names></name>, <name><surname>Lindskog</surname><given-names>C</given-names></name>, <name><surname>Oksvold</surname><given-names>P</given-names></name>, <name><surname>Mardinoglu</surname><given-names>A</given-names></name>, <name><surname>Sivertsson</surname><given-names>Å</given-names></name>, <name><surname>Kampf</surname><given-names>C</given-names></name>, <name><surname>Sjöstedt</surname><given-names>E</given-names></name>, <name><surname>Asplund</surname><given-names>A</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>Tissue-based map of the human proteome</article-title>. <source/>Science
<volume>347</volume>: <fpage>1260419</fpage>.<pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C57">
<mixed-citation publication-type="journal"><name><surname>Vlasova</surname><given-names>TI</given-names></name>, <name><surname>Stratton</surname><given-names>SL</given-names></name>, <name><surname>Wells</surname><given-names>AM</given-names></name>, <name><surname>Mock</surname><given-names>NI</given-names></name>, <name><surname>Mock</surname><given-names>DM</given-names></name>. <year>2005</year>
<article-title>Biotin deficiency reduces expression of <italic>SLC19A3</italic>, a potential biotin transporter, in leukocytes from human blood</article-title>. <source/>J Nutr
<volume>135</volume>: <fpage>42</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">15623830</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C58">
<mixed-citation publication-type="journal"><name><surname>Yamada</surname><given-names>K</given-names></name>, <name><surname>Miura</surname><given-names>K</given-names></name>, <name><surname>Hara</surname><given-names>K</given-names></name>, <name><surname>Suzuki</surname><given-names>M</given-names></name>, <name><surname>Nakanishi</surname><given-names>K</given-names></name>, <name><surname>Kumagai</surname><given-names>T</given-names></name>, <name><surname>Ishihara</surname><given-names>N</given-names></name>, <name><surname>Yamada</surname><given-names>Y</given-names></name>, <name><surname>Kuwano</surname><given-names>R</given-names></name>, <name><surname>Tsuji</surname><given-names>S</given-names></name>, <etal></etal>
<year>2010</year>
<article-title>A wide spectrum of clinical and brain MRI findings in patients with <italic>SLC19A3</italic> mutations</article-title>. <source/>BMC Med Genet
<volume>11</volume>: <fpage>1471</fpage>–<lpage>2350</lpage>.</mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C59">
<mixed-citation publication-type="journal"><name><surname>Ygberg</surname><given-names>S</given-names></name>, <name><surname>Naess</surname><given-names>K</given-names></name>, <name><surname>Eriksson</surname><given-names>M</given-names></name>, <name><surname>Stranneheim</surname><given-names>H</given-names></name>, <name><surname>Lesko</surname><given-names>N</given-names></name>, <name><surname>Barbaro</surname><given-names>M</given-names></name>, <name><surname>Wibom</surname><given-names>R</given-names></name>, <name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Wedell</surname><given-names>A</given-names></name>, <name><surname>Wickström</surname><given-names>R</given-names></name>. <year>2016</year>
<article-title>Biotin and thiamine responsive basal ganglia disease—a vital differential diagnosis in infants with severe encephalopathy</article-title>. <source/>Eur J Paediatr Neurol
<volume>20</volume>: <fpage>457</fpage>–<lpage>461</lpage>.<pub-id pub-id-type="pmid">26975589</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C60">
<mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>W-Q</given-names></name>, <name><surname>Al-Yamani</surname><given-names>E</given-names></name>, <name><surname>Acierno</surname><given-names>JS</given-names><suffix>Jr</suffix></name>, <name><surname>Slaugenhaupt</surname><given-names>S</given-names></name>, <name><surname>Gillis</surname><given-names>T</given-names></name>, <name><surname>MacDonald</surname><given-names>ME</given-names></name>, <name><surname>Ozand</surname><given-names>PT</given-names></name>, <name><surname>Gusella</surname><given-names>JF</given-names></name>. <year>2005</year>
<article-title>Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in <italic>SLC19A3</italic></article-title>. <source/>Am J Hum Genet
<volume>77</volume>: <fpage>16</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">15871139</pub-id></mixed-citation>
</ref>
<ref id="WHITFORDMCS001909C61">
<mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>F</given-names></name>, <name><surname>Tanaka</surname><given-names>K</given-names></name>, <name><surname>Pan</surname><given-names>Z</given-names></name>, <name><surname>Ma</surname><given-names>J</given-names></name>, <name><surname>You</surname><given-names>G</given-names></name>. <year>2004</year>
<article-title>The role of glycine residues in the function of human organic anion transporter 4</article-title>. <source/>Mol Pharmacol
<volume>65</volume>: <fpage>1141</fpage>–<lpage>1147</lpage>.<pub-id pub-id-type="pmid">15102942</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>